Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18431665 | 0.96 | RXRA (0.31) | RXRARXRBRXRG | |
| SCHEMBL21166373 | 0.95 | RXRA (0.34) | RXRARXRBRXRG | |
| SCHEMBL18896626 | 0.89 | RXRA (0.31) | RXRARXRBRXRG | |
| SCHEMBL19176483 | 0.88 | RXRA (0.33) | RXRARXRBRXRG | |
| SCHEMBL22013220 | 0.88 | RXRA (0.33) | RXRARXRBRXRG | |
| SCHEMBL18737541 | 0.86 | RXRA (0.35) | RXRARXRBRXRG | |
| SCHEMBL21166368 | 0.84 | RXRA (0.34) | RXRARXRBRXRG | |
| SCHEMBL18743181 | 0.83 | RXRA (0.30) | RXRARXRBRXRG | |
| SCHEMBL18431662 | 0.82 | NPC1 (0.33) | RXRARXRBRXRG | |
| SCHEMBL24690506 | 0.80 | RXRA (0.33) | RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844077-B2 | Thiazolyl-containing compounds for treating proliferative diseases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200165267-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200165267-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | BTK, BCL9L, MCL1 | RXRA 1699/4885RXRB 1272/4885RXRG 911/4885 |
| US-10844077-B2 | Thiazolyl-containing compounds for treating proliferative diseases | BTK, BCL9L, MCL1 | RXRA 1699/4885RXRB 1272/4885RXRG 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.